Influenza
Conditions
Brief summary
This study assesses immunogenicity and safety of NBP607-QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled, and each subject is administered with single or two doses of vaccines depending on previous vaccination history.
Detailed description
This is a multi-national, multi-center, randomized, double blinded, parallel-group study to assess the immunogenicity and safety of NBP607-QIV compared to Agrippal which are indicated for active immunization for the the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled. Each subject is administered with single or two doses of vaccines depending on previous vaccination history, and randomly assigned in 2:1 ratio. Stratified randomization for trial site and age strata is used to achieve the balance of treatment assignment. Total of three or five visits are scheduled depeding on dosing schedule. For subjects assigned to single-dose vaccination schedule, blood sampling is conducted for immunogenicity assessment before and 4 weeks after single vaccination at Visit 1 and 3 respectively. Safety is monitored 3 days, 4 weeks after vaccination through Visit 2\* and 3 (\* telephone contact). For subjects assigned to two-dose vaccination schedule, blood sampling is conducted before first vaccination and 4 weeks after second vaccination at Visit 1 and Visit 5 respectively. Safety is monitored 3 days, 4 weeks after each vaccination through Visit 2\*, 3, 4\*, and 5 (\* telephone contact)
Interventions
BIOLOGICALNBP607-QIV
Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
BIOLOGICALAgrippal
Influenza virus surface antigens of three strains (trivalent)
Sponsors
SK Bioscience Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Months to 35 Months
Healthy volunteers
Yes
Inclusion criteria
* Children aged 6 to 35 months * Those who were normal gestational age at birth (for children aged 6 months to \<1 year) * Those who have provided written informed consent to study participation and compliance with study instructions after being informed of and understand details of the study
Exclusion criteria
* Those with any immunodeficiency disease or malignancy * Those with hypersensitivity to vaccination * Those who are contraindicated for intramuscular injection due to thrombocytopenia or other coagulopathy * Those with history of treatment with any of immunosuppressants or immunoregulators within 12 weeks prior to screening * Those with history of receiving blood product or treatment with immunoglobulin within 24 weeks prior to screening * Those with history of influenza vaccination within 24 weeks prior to screening * Those with any severe chronic conditions that interfere with study participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Post-vaccination GMT(Geometric Mean Titer) by HI(Hemagglutination-inhibition) assay for the common strains (A/H1N1, A/H3N2, and B/Victoria) | 4 weeks after last IP(Investigational Product) vaccination | Post-vaccination GMT will be adjusted for pre-vaccination titer |
| Seroconversion rate by HI assay for the common strains (A/H1N1, A/H3N2, and B/Victoria) | 4 weeks after last IP(Investigational Product) vaccination | Seroconversion rate is defined as the proportion of subjects who meet either of the following criteria: 1. Post-vaccination HI titer of ≥1:40 for subjects with pre-vaccination HI titer of \<1:10 2. Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥1:10 |
| Seroconversion rate by HI assay for the exclusive strain (B/Yamagata) | 4 weeks after last IP(Investigational Product) vaccination | Seroconversion rate is defined as the proportion of subjects who meet either of the following criteria: 1. Post-vaccination HI titer of ≥1:40 for subjects with pre-vaccination HI titer of \<1:10 2. Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥1:10 |
| GMR(Geometric mean ratio) by HI assay for the exclusive strain (B/Yamagata) | 4 weeks after last IP(Investigational Product) vaccination | The fold-rise of the geometric mean HI titer from pre- to post-vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vital sign | 4 weeks after last IP(Investigational Product) vaccination | Body temperature will be assessed |
| Seroprotection rate by HI assay for all strains | 4 weeks after last IP(Investigational Product) vaccination | Seroprotection rate is defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40 |
| Weight | 4 weeks after last IP(Investigational Product) vaccination | Weight in kilograms will be assessed |
| Height | 4 weeks after last IP(Investigational Product) vaccination | Height in centimeters will be assessed |
| CHMP(Committee for Medicinal Products for Human Use) criteria assessment for the common strains (A/H1N1, A/H3N2, and B/Victoria) | 4 weeks after last IP(Investigational Product) vaccination | CHMP criteria for seroconversion rate, GMR(Geometric Mean Ratio) will be assessed |
| Consistency of immunogenicity among countries | 4 weeks after last IP(Investigational Product) vaccination | Post-vaccination GMT and seroconversion rate for the common strains (A/H1N1, A/H3N2, and B/Victoria), and CHMP criteria for seroconversion rate and GMR for the exclusive strain (B/Yamagata) will be assessed |
| Percentage of participants with Adverse Events(AEs) | 7 days for Solicited AE and 4 weeks for Unsolicited AE, SAE after last IP(Investigational Product) vaccination | Incidence rate of Solicited AE, unsolicited AE, SAE(Serious Adverse Event) will be assessed |
Countries
South Korea
Outcome results
None listed